Group 1 - The core viewpoint of the news is the successful listing of Guangzhou Yinnuo Pharmaceutical Group Co., Ltd. on the Hong Kong Stock Exchange, marking a significant milestone for Everbright Holdings in the healthcare sector [1][3] - Everbright Holdings' investment in Yinnuo Pharmaceutical was completed in December 2021, highlighting its strategic focus on the medical and health sector [1] - The Guang控泰州 Fund, initiated by Everbright Holdings and Taizhou Medical High-tech Zone, has a total scale of 1 billion yuan and focuses on investments in biomedicine, high-performance medical devices, and other industries [1] Group 2 - Yinnuo Pharmaceutical specializes in innovative therapies for diabetes and other metabolic diseases, rapidly rising in the field since its establishment in 2014 [3] - The company is the first in Asia and the third globally to advance a novel human GLP-1 receptor agonist to the registration approval stage, with its core product, Isupatide, receiving approval from the Chinese regulatory authority [3] - Yinnuo is actively expanding globally, having obtained BLA approval in Macau for Isupatide to treat Type 2 Diabetes, indicating its strong R&D capabilities and promising future in innovative drug development [3]
光大控股（165.HK）投资项目「银诺医药」成功登陆港交所
Xin Lang Cai Jing·2025-08-15 11:14